Early Response to Everolimus Therapy Detected on Ga-68-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor

ÖZKAN E., SOYDAL Ç., Semirgin S. U., Yapici O., ATMACA A., Demirag G.

CLINICAL NUCLEAR MEDICINE, cilt.41, sa.7, ss.561-563, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Editöre Mektup
  • Cilt numarası: 41 Sayı: 7
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1097/rlu.0000000000001242
  • Dergi Adı: CLINICAL NUCLEAR MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.561-563
  • Anahtar Kelimeler: Ga-68-DOTATATE PET/CT, everolimus, treatment response, RADIONUCLIDE THERAPY
  • Ankara Üniversitesi Adresli: Evet

Özet

Everolimus is a mammalian target of rapamycin inhibitor that has been recently approved for the treatment of patients with advanced progressive pancreatic neuroendocrine tumor. Here, we present a case in which an early therapy response to everolimus was effectively demonstrated by Ga-68-DOTATATE PET/CT.